Oncolytics Biotech Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Mar 7, 2025 · CIK: 1129928

Sentiment: neutral

Topics: sec-filing, 6-K, foreign-private-issuer

Related Tickers: ONC

TL;DR

ONCOLYTICS BIOTECH (ONC) filed a 6-K, confirming foreign private issuer status and 20-F annual report filing.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on March 7, 2025, reporting as a foreign private issuer. The filing indicates the company is submitting its report under the 1934 Act and will file its annual reports under Form 20-F. The company's principal executive offices are located in Calgary, Alberta, Canada.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of March 2025.

Which form will Oncolytics Biotech Inc. use for its annual reports?

Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.

Where are Oncolytics Biotech Inc.'s principal executive offices located?

The principal executive offices of Oncolytics Biotech Inc. are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

What is the SEC file number for Oncolytics Biotech Inc.?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

What is the filing date of this Form 6-K?

This Form 6-K was filed as of March 7, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 7, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing